Trial Number
404-23
Condition
Pediatric Cancer
Participant Age Range
1 year to 30 years
Participant Gender
Any
Enrolling Participants
No
Overview
“A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)”
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma.